For checkpoint inhibition, PDL1 has been proposed as a putative biomarker, as pembrolizumab (anti-PD 1) is approved in non-small-cell lung carcinoma (NSCLC) only in patients whose tumor PD-L1 levels are ≥50% [32]. Here, RPL17 is linked to non-small cell lung carcinoma.